Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) shares, rose in value on Wednesday, July 09, with the stock price up by 3.72% to the previous day’s close as strong demand from buyers drove the stock to $7.24.
Actively observing the price movement in the last trading, the stock closed the session at $6.98, falling within a range of $6.9 and $7.395. The value of beta (5-year monthly) was -0.587. Referring to stock’s 52-week performance, its high was $7.27, and the low was $1.62. On the whole, AMLX has fluctuated by 35.83% over the past month.
With the market capitalization of Amylyx Pharmaceuticals Inc currently standing at about $645.38 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-08.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that AMLX’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 100% Buy.
The stock’s technical analysis shows that the price of AMLX currently trading nearly 20.34% and 34.09% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 71.89, while the 7-day volatility ratio is showing 9.35% which for the 30-day chart, stands at 8.12%. Furthermore, Amylyx Pharmaceuticals Inc (AMLX)’s beta value is -0.49.
A comparison of Amylyx Pharmaceuticals Inc (AMLX) with its peers suggests the former has fared considerably weaker in the market. AMLX showed an intraday change of 3.72% in last session, and over the past year, it grew by 91.53%%.
Data on historical trading for Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) indicates that the trading volumes over the past 10 days have averaged 2.91 and over the past 3 months, they’ve averaged 1.32 million. According to company’s latest data on outstanding shares, there are 89.08 million shares outstanding.
Nearly 26.74% of Amylyx Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 80.20% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.04 million shares as on 2025-06-13, resulting in a short ratio of 4.43. According to the data, the short interest in Amylyx Pharmaceuticals Inc (AMLX) stood at 500.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 4.97 million. The stock has risen by 320.93% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AMLX stock heading into the next quarter.
